Clinical Trials
4 trialsNCT04783415 2024-12-02
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02268851 2024-11-15
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04692155 2023-09-28
CHOP U2
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn